AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Allogene Therapeutics, Inc.
Video analysis: ALLO
All videosNo video analysis for this stock yet. Request one from our team.
News: ALLO
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Frazier Life Sciences Management L.P. Acquires 18,650,000 Shares of Allogene Therapeutics, Inc. $ALLO
Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,446,668 shares of the company's stock after acquiring an additional 18,650,000 shares during the quarter.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.
Deutsche Bank AG Purchases Shares of 281,949 Allogene Therapeutics, Inc. $ALLO
Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,949 shares of the company's stock, valued at approximately $586,000. Deutsche Bank AG owned about 0.08% of Allogene
Connor Clark & Lunn Investment Management Ltd. Invests $671,000 in Allogene Therapeutics, Inc. $ALLO
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 322,827 shares of the company's stock, valued at approximately $671,000. Connor Clark
Allogene Therapeutics Announces Participation in September Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?
Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
